What Is CJC-1295 with DAC? A Simple Introduction to This Long-Acting Research Peptide

CJC-1295 with DAC is a synthetic research peptide designed to interact with the body’s growth hormone releasing hormone pathway, often shortened to the GHRH pathway. This pathway is involved in signalling the pituitary gland to release growth hormone, which then influences wider biological processes connected to growth, repair, metabolism, body composition, and IGF-1 production.

CJC-1295 has attracted interest in peptide research because its development as a longer-acting version of a GHRH analogue. Rather than directly replacing growth hormone, CJC-1295 is studied for its ability to encourage the body’s growth hormone signalling system. Giving it an interesting peptide for research connected to recovery, body composition, lean tissue, ageing biology, and metabolic function.

The key feature of CJC-1295 with DAC is the DAC component. DAC stands for Drug Affinity Complex. In simple terms, DAC was added to help the peptide bind to albumin, a natural protein found in the blood. This albumin binding allows the peptide to remain active in the body for much longer than it would without DAC. Research has reported a human half-life of around 5.8 to 8.1 days, with IGF-1 levels remaining above baseline for up to 28 days after multiple doses in one clinical study.

This is why DAC matters. Without DAC, CJC-1295-style peptides are generally considered shorter acting. With DAC, the peptide was designed to have a more prolonged effect on the GH/IGF-1 axis. One published review explains that the extended half-life of CJC-1295 is linked to its ability to bind to endogenous serum albumin, giving it a much longer duration of action.

From a research perspective, this longer action may be useful because it creates a more sustained biological signal. Instead of a short pulse, CJC-1295 with DAC has been studied for its ability to produce longer-lasting increases in growth hormone and IGF-1 activity. Another study noted that CJC-1295 selectively and covalently binds to endogenous albumin after injection, which extends its half-life and duration of action.

For athletes, CJC-1295 needs careful consideration because growth hormone secretagogues and related compounds are generally prohibited in sport under anti-doping rules. Anyone competing in tested sport should treat this category with caution and check the relevant anti-doping guidance before making any decisions.

The best way to understand CJC-1295 with DAC is as a long-acting research peptide designed to support scientific investigation into growth hormone signalling. The DAC component is used because it extends the peptide’s activity by allowing it to bind to albumin, making it much longer lasting than shorter-acting versions.

Why Is DAC Used?

DAC is used to extend the active life of CJC-1295.

Without DAC, similar GHRH-style peptides are shorter acting and clear from the body more quickly. With DAC, CJC-1295 can bind to albumin in the bloodstream, which helps protect it from rapid breakdown and allows it to remain active longer.

This longer duration is the main reason researchers and peptide users often separate the two categories:

Key Takeaway

CJC-1295 with DAC is a long-acting GHRH analogue studied for its role in growth hormone and IGF-1 signalling. The DAC component is used to extend the peptide’s half-life by helping it bind to albumin in the blood, allowing for a longer-lasting biological signal.

Important Disclaimer

This article is for educational and informational purposes only. It is not medical advice, dosage guidance, or a recommendation to use CJC-1295 with DAC or any other peptide.

CJC-1295 with DAC is not currently FDA-approved as a licensed medicine for treating, curing, or preventing any medical condition. Anyone considering peptides, hormone-related compounds, supplements, or any health-related intervention should speak with a qualified healthcare professional first.